Insmed Incorporated Message Board

100 Million
3 million addition shares = done

by iounothjing1 •5/15/2013 1,494,659
4/30/2013 1,345,499
149,160 shares up

Leerink Swann today maintained an Outperform rating on Insmed (NASDAQ: INSM) and raised its price target to $22.00 (from $13.00). Increased bullishness follows additional data on Arikace in cystic fibrosis (CF) and non-tuberculous mycobacteria (NFM).

increasing our price target to $18
from $11.

by iounothjing1 • .
they will have a field day next week

3 million share dilution Approved
non-employee directors and other non-employee advisors or service providers of the Registrant and its affiliates under the Insmed Incorporated 2013 Incentive Plan (the “Plan”). The total number of shares of Common Stock available for issuance under the Plan is 3,000,000 plus any shares authorized for issuance under the Registrant’s Amended and Restated 2000 Stock Incentive Plan (the “Prior Plan”) that, as of May 23, 2013

Thank you blank and Historian.

Yep... He's on it...Please Read earlier publications

Sentiment: Strong Buy

You could be right. Do I have the correct information below?

David Geller is listed giving a presentation entitled....Delivering Drugs to the Airways: DPI or Nebulizer. This will be taking place at the 36th European Cystic Fibrosis Society Conference which takes place June 12-15 in Lisbon, Portugal.

Lisbon, 12-15th of June

Sentiment: Strong Buy

blank,
When is this scheduled to take place?

Sec investigation convinces me... Not having one!,

Sentiment: Strong Buy

wrong!
my bad: (prompted by Fud's other post):
$25.7M was raised with the unlawful offering of stock at below book value. I was thinking it was $6M raised (I could not be bothered to check my records yesterday) whereas it was 6M additional shareholder dilution (for $25.7M we didn't need).
that accounts for the $49.something million unused from the previous S-3.
The $20M loan did not fall under the remit of S-3 (it was/is a straightforward loan)

Wall St. Cheat Sheet » Business Recaps »
Healthcare Stock Stories For Tuesday Investment Wellness

May 22 (Reuters) - Insmed Inc : * Canaccord Genuity raises price target to $17 from $12; rating buy

increasing our price target to $18
from $11.

Leerink Swann today maintained an Outperform rating on Insmed (NASDAQ: INSM) and raised its price target to $22.00 (from $13.00). Increased bullishness follows additional data on Arikace in cystic fibrosis (CF) and non-tuberculous mycobacteria (NFM).

remember that analyst actions should be taken with a grain of salt as they rarely have any long-term bearing on a stocks' share price or your investing thesis. The reality here is that Insmed still doesn't have a drug approved by the Food and Drug Administration, it's burning cash, and it could be at least two more years before it gets Arikace in front of the European Medicines Agency for an approval decision. A U.S. decision will be yet another year or two beyond that. With a cash burn rate that I anticipate will be right around $50 million annually, it won't be long before Insmed needs cash again and reaches to potentially dilutive offerings to accomplish this. I'd strongly suggest keeping your distance